People · Operator
Named in public records as an officer, director or promoter · active 2008–2018 · Other Technology, Biotechnology, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OrderMark, Inc. | — | Other Technology | Series D+ | $139.3M | $3.2B | 2017 |
| Xceive Corp | — | Other Technology | Series A | $86.4M | $43.9M | 2008 |
| Oraya Therapeutics Inc | — | Other Technology | Series B | $74.9M | $765.4M | 2009 |
| Kona Medical, Inc. | — | Biotechnology | Series B | $61.6M | $396.9M | 2010 |
| Flo Water, Inc. | — | Retailing | Series B | $19.8M | $100.9M | 2018 |
| Faculte, Inc. | — | Other Technology | Seed | $8.5M | $102.2M | 2009 |
| TAGENT Corp | — | Other Technology | Seed | $6.2M | $89.3M | 2009 |
| Provade, Inc | — | Other Technology | Seed | $6.1M | $97.5M | 2009 |
| MediSens Wireless, Inc. | — | Other Technology | Seed | $3.8M | $89.1M | 2014 |
| RADAR Corp | — | Other Technology | Seed | $2.0M | $68.1M | 2009 |
Peter Cohn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Cohn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Halak | 2 | 10 |
| Michael Gertner | 2 | 2 |
| James Taylor | 1 | 12 |
| Chris Moody | 1 | 9 |
| Paul Allen | 1 | 8 |
| Reza Zadno | 1 | 7 |
| Henry A. Plain, Jr. | 1 | 7 |
| Guido Neels | 1 | 7 |
| Immanuel Thangaraj | 1 | 6 |
| David Fleshman | 1 | 5 |
| David Sachs | 1 | 5 |
| Mark Brooks | 1 | 5 |
| Hank Plain | 1 | 5 |
| Han Kim | 1 | 4 |
| MICHAEL JACOBS | 1 | 4 |
| John Onopchenko | 1 | 4 |
| James Jones | 1 | 4 |
| Patrick Quirk | 1 | 3 |
| Christopher A. Shen | 1 | 3 |
| Jeffrey Housenbold | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.